DXCM · Dexcom Inc
$71.54
+1.06 (+1.50%)
At close · Jul 24
Market Cap
$27.20B
Shares
385.87M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Kevin Sayer | Chairman | $16,282,598 |
| Jacob Leach | CEO | $7,985,960 |
| Jereme Sylvain | CFO | $7,077,902 |
| Jon Coleman | Executive Vice President, Chief Commercial Officer | $6,745,295 |
| Michael Brown | Executive Vice President, Chief Legal Officer | $6,343,856 |
| Sadie Stern | Executive Vice President, Chief Human Resources Officer | $6,253,131 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Kevin Sayer | CEO | $15,828,797 |
| Teri L. Lawver | Executive Vice President, Chief Commercial Officer | $6,452,827 |
| Jacob Leach | COO | $5,922,271 |
| Jereme Sylvain | CFO | $5,851,112 |
| Michael Brown | Executive Vice President, Chief Legal Officer | $4,964,895 |
| Sadie M. Stern | Executive Vice President, Chief Human Resources Officer | $4,908,488 |
| Sadie Stern | Executive Vice President, Chief Human Resources Officer | $4,908,488 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Kevin Sayer | CEO | $15,712,244 |
| Teri L. Lawver | Executive Vice President, Chief Commercial Officer | $6,526,593 |
| Jacob Leach | COO | $4,938,023 |
| Michael Brown | Executive Vice President, Chief Legal Officer | $4,342,792 |
| Jereme Sylvain | CFO | $4,254,900 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Kevin Sayer | CEO | $15,435,652 |
| Michael Brown | Executive Vice President, Chief Legal Officer | $5,746,278 |
| Jacob Leach | COO | $4,427,208 |
| Girish Naganathan | CTO | $4,051,531 |
| Jereme Sylvain | CFO | $3,538,881 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Kevin Sayer | CEO | $11,985,324 |
| Jacob Leach | COO | $5,708,273 |
| Chad M. Patterson | Executive Vice President, Global Marketing | $4,875,133 |
| Paul Flynn | Executive Vice President, Global Revenue | $4,866,159 |
| Jereme Sylvain | CFO | $4,738,880 |
| Quentin Blackford | CFO | $4,621,854 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Kevin Sayer | CEO | $13,804,156 |
| Jeffrey C. Moy | EVP, Operations | $7,478,553 |
| Richard B. Doubleday | Executive Vice President, Chief Commercial Officer | $5,853,342 |
| Quentin Blackford | CFO | $5,128,521 |
| Jacob Leach | COO | $4,370,582 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Kevin Sayer | CEO | $10,279,373 |
| Quentin Blackford | CFO | $3,806,896 |
| Richard B. Doubleday | Executive Vice President, Chief Commercial Officer | $3,274,184 |
| Andrew K. Balo | Executive Vice President, Global Medical Affairs, Access and Evidence | $3,022,690 |
| Steven R. Pacelli | Executive Vice President, Managing Director, Dexcom Ventures | $3,020,341 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Kevin Sayer | CEO | $9,554,123 |
| Quentin Blackford | CFO | $3,391,643 |
| Richard B. Doubleday | Executive Vice President, Chief Commercial Officer | $3,207,458 |
| Andrew K. Balo | Executive Vice President, Global Medical Affairs, Access and Evidence | $3,174,638 |
| Steven R. Pacelli | Executive Vice President, Managing Director, Dexcom Ventures | $3,172,309 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Kevin Sayer | CEO | $7,924,868 |
| Quentin Blackford | CFO | $5,115,201 |
| Andrew K. Balo | Executive Vice President, Global Medical Affairs, Access and Evidence | $3,016,911 |
| Steven R. Pacelli | Executive Vice President, Managing Director, Dexcom Ventures | $2,919,155 |
| Richard B. Doubleday | Executive Vice President, Chief Commercial Officer | $2,919,155 |
Key facts
CIK
1093557
CUSIP
252131107
13F (30d)
208 filings
203 filers
Visit website
Investor relations